UNSPSC 51292502: Itasetron

This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C16H20N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00S0D0OEKR, chemically known as 2-oxo-n-1alphah,5alphah-tropan-3alpha-yl-1-benzimidazolinecarboxamide but generally known as itasetron, which bears US NIH Compound Identifier 60761. European Medicines Agency schedules Itasetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08350MIG.

UNSPSC 51292502 Itasetron is a Commodity-tier code that in practice spans pharmaceutical procurement across state and local health agencies, though the code's nominal scope does not align cleanly with recent state and local solicitations tagged under it. The three most recent opportunities show a divergence: one solicitation from Seminole County, Florida (IFB60459723LAS, posted June 30, 2026) procures naloxone and drug deactivation systems for community health support through a competitive bid process with quarterly deliveries; a second from Texas Health and Human Services Commission (RFI HHS0017013, posted April 3, 2026) seeks vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and a third from the Minnesota Multistate Cooperative Purchasing Alliance (S1070000015802, posted January 20, 2026) establishes multi-state contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson wholesalers. The issuing bodies represent a mix of county public health departments, state health agencies, and cooperative purchasing alliances, with MMCAP operating as a multi-state vehicle serving participating state and local government facilities. No recent opportunities in the source specifically address itasetron (a 5-HT3 receptor antagonist) as a discrete procurement line item.

The geographic spread of recent activity centers on Florida, Texas, and Minnesota, with MMCAP's cooperative vehicle extending across multiple jurisdictions including Oregon. Seminole County's naloxone procurement is an IFB with a response deadline of July 26, 2023 (note: posted date shows June 30, 2026, with delivery and insurance compliance required); the Texas HHS Commission's RFI carries a response deadline of April 3, 2026 and represents exploratory market research rather than a formal competitive solicitation; and MMCAP's RFP, due March 26, 2026, uses a 75-percent weighting on price competitiveness and requires vendors to contract with at least two of three authorized wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, and pay a 3 percent administrative fee. The mismatch between the code's nominal scope (itasetron) and the actual procurement activity (broad pharmaceutical, naloxone, and OTC product sourcing) suggests this code sees limited activity specifically targeting the named antiemetic drug and instead functions as a catch-all for state and local pharmaceutical procurement when more specific codes are unavailable.